People · Operator
Named in public records as an officer, director or promoter · active 2009–2022 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Embera Neurotherapeutics, Inc. | — | Pharmaceuticals | Series A | $14.6M | $189.8M | 2009 |
| Osmol Therapeutics, Inc. | — | Biotechnology | Seed | $2.9M | $41.5M | 2022 |
Robert Linke at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Linke on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Franz Hefti | 1 | 6 |
| Ross Barrett | 1 | 5 |
| Joseph Lovett | 1 | 4 |
| Ross P. Barrett | 1 | 4 |
| Robert Berman | 1 | 4 |
| Brian Dixon | 1 | 3 |
| Vlad Coric | 1 | 2 |
| Joseph P. Lovett | 1 | 2 |
| Joseph B. Lovett | 1 | 1 |
| Franz B. Hefti | 1 | 1 |
| Ross B. Barrett | 1 | 1 |
| Franz P. Hefti | 1 | 1 |
| John B. Beaird | 1 | 1 |
| Nicholas E. Goeders | 1 | 1 |
| Michael Ehrlich | 1 | 1 |
| Robert B. Linke | 1 | 1 |
| Nicholas Goeders | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.